A PHASE 2, OPEN LABEL, MULTI-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TAS-115 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)

Trial Profile

A PHASE 2, OPEN LABEL, MULTI-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TAS-115 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs TAS 115 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 13 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 30 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top